|
Records 1-30 (of 160 Records) |
| Query Trace: Cystic Fibrosis[original query] |
|---|
| Cystic fibrosis transmembrane conductance regulator modulators attenuate platelet activation and aggregation in blood of healthy donors and COVID-19 patients. Asmus Erik, et al. The European respiratory journal 2023 0 0. (3) |
| Clinical prediction rules for adverse evolution in patients with COVID-19 by the Omicron variant. Portuondo-Jiménez Janire, et al. International journal of medical informatics 2023 0 0. 105039 
|
| Immunogenicity, Safety and Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA Vaccination in Immunocompromised Adolescents and Young Adults: A systematic Review and Meta-Analyses P Katoto et al, MEDRXIV, January 20, 2023
The overall estimated proportion of combined local and systemic reactions after the first BNT162b2 vaccination was 30%[95% CI: 17-42%] and slightly rose to 32% [95% CI: 19-44%] after the second dose. Rheumatic illnesses had the highest rate of AEFI (40%[95% CI: 16-65%]), while cystic fibrosis had the lowest (27%[95% CI: 17%-38%]). Hospitalizations for AEFIs were rare.
|
| SARS-CoV-2 viral entry and replication is impaired in Cystic Fibrosis airways due to ACE2 downregulation. Bezzerri Valentino et al. Nature communications 2023 1 (1) 132 
As an inherited disorder characterized by severe pulmonary disease, cystic fibrosis could be considered a comorbidity for coronavirus disease 2019. Instead, current clinical evidence seems to be heading in the opposite direction. To clarify whether host factors expressed by the Cystic Fibrosis epithelia may influence coronavirus disease 2019 progression, here we describe the expression of SARS-CoV-2 receptors in primary airway epithelial cells. We show that angiotensin converting enzyme 2 (ACE2) expression and localization are regulated by Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel.
|
| Gain- and Loss-of-Function CFTR Alleles Are Associated with COVID-19 Clinical Outcomes. Baldassarri Margherita, et al. Cells 2022 0 0. (24)
|
| The Impact of Elexacaftor/Ivacaftor/Tezacaftor on Cystic Fibrosis Patients Who Acquire COVID-19 Infection. Miles Brittany, et al. Cureus 2022 0 0. (9) e29276
|
| Telemonitoring for Cystic fibrosis patients of Bambino Gesù Children's Hospital during COVID-19. Federici A, et al. La Clinica terapeutica 2022 0 0. (5) 440-442 
|
| Determinants of coronavirus disease 2019 infection by artificial intelligence technology: A study of 28 countries. Peng Hsiao-Ya, et al. PloS one 2022 0 0. (8) e0272546
|
| Identification of differentially expressed genes and their major pathways among the patient with COVID-19, cystic fibrosis, and chronic kidney disease. Babu Golap, et al. Informatics in medicine unlocked 2022 0 0. 101038
|
| The omicron wave modifies the COVID-19 paradigm in children with cystic fibrosis. Thouvenin Guillaume, et al. The Journal of infectious diseases 2022 0 0. |
| TMED3 Complex Mediates ER Stress-Associated Secretion of CFTR, Pendrin, and SARS-CoV-2 Spike. Park Hak, et al. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 2022 0 0. e2105320
|
| Geographical distribution of cystic fibrosis carriers as population genetic determinant of COVID-19 spread and fatality in 37 countries. Gabbi Chiara, et al. The Journal of infection 2022 0 0.
|
| Proteomic Analysis of Human Sputum for the Diagnosis of Lung Disorders: Where Are We Today? D'Amato Maura, et al. International journal of molecular sciences 2022 0 0. (10)
|
| Telemedicine of patients with cystic fibrosis during the COVID-19 pandemic. Costa Rafaella Lima Ferreira, et al. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo 2022 0 0. e2021118
|
| Discovering Common Pathophysiological Processes between COVID-19 and Cystic Fibrosis by Differential Gene Expression Pattern Analysis. Hasan Md Tanvir, et al. BioMed research international 2022 0 0. 8078259
|
| Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis. Michos Athanasios, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2022 0 0.
|
| Risk Assessment for Patients with Chronic Respiratory Conditions in the Context of the SARS-CoV-2 Pandemic Statement of the German Respiratory Society with the Support of the German Association of Chest Physicians. Lommatzsch Marek, et al. Respiration; international review of thoracic diseases 2022 0 0. (3) 307-320
|
| The impact of COVID-19 upon the delivery of exercise services within cystic fibrosis clinics in the United Kingdom. Tomlinson Owen W, et al. The clinical respiratory journal 2022 0 0.
|
| Cystic fibrosis telemedicine in the era of COVID-19. Rad Elika J, et al. JAMIA open 2022 0 0. (1) ooac005
|
| CONCERNS FOR PEOPLE WITH CYSTIC FIBROSIS (PWCF) WHEN TRAVELLING PRE COVID-19. O'Doherty Megan, et al. The Ulster medical journal 2022 0 0. (1) 53-55 |
| Changes in Care during the COVID-19 Pandemic for People with Cystic Fibrosis. Sanders Don B, et al. Annals of the American Thoracic Society 2022 0 0.
|
| Synthesis and bioactivity of readily hydrolysable novel cationic lipids for potential lung delivery application of mRNAs. Pei Yihua, et al. Chemistry and physics of lipids 2022 0 0. 105178
|
| Poor Respiratory Health Following Relapsing SARS-CoV-2 Infection in Children with Cystic Fibrosis. Dhochak Nitin, et al. Indian journal of pediatrics 2022 0 0. |
| PBPK-led guidance for cystic fibrosis patients taking elexacaftor-tezacaftor-ivacaftor with nirmatrelvir-ritonavir for the treatment of COVID-19 E Hong et al, MEDRXIV, January 22, 2022 |
| Factors for severe outcomes following SARS-CoV-2 infection in people with cystic fibrosis in Europe. Jung Andreas, et al. ERJ open research 2022 0 0. (4)
|
| Impact of the COVID-19 pandemic: How our response is shaping the future of cystic fibrosis care. Sabadosa Kathryn A, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 1-2 |
| Financial impacts of the COVID-19 pandemic on cystic fibrosis care: lessons for the future. Sawicki Gregory S, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 16-20 
|
| Barriers and facilitators to implementing telehealth services during the COVID-19 pandemic: A qualitative analysis of interviews with cystic fibrosis care team members. Van Citters Aricca D, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 23-28
|
| Design and methods for understanding the state of cystic fibrosis care amid the COVID-19 pandemic. Dowd Christopher, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 3-8
|
| Impact of COVID-19 on mental health: Effects on screening, care delivery, and people with cystic fibrosis. Smith Beth A, et al. Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society 2021 0 0. 31-38 |
Disclaimer: Articles listed in the Public Health
Knowledge Base are selected by the CDC Office of Public Health
Genomics to provide current awareness of the literature and news.
Inclusion in the update does not necessarily represent the views of
the Centers for Disease Control and Prevention nor does it imply
endorsement of the article's methods or findings. CDC and DHHS assume
no responsibility for the factual accuracy of the items presented. The
selection, omission, or content of items does not imply any
endorsement or other position taken by CDC or DHHS. Opinion, findings
and conclusions expressed by the original authors of items included in
the update, or persons quoted therein, are strictly their own and are
in no way meant to represent the opinion or views of CDC or DHHS.
References to publications, news sources, and non-CDC Websites are
provided solely for informational purposes and do not imply
endorsement by CDC or DHHS.
- Page last reviewed:Feb 1, 2023
- Page last updated:Mar 25, 2023
- Content source: